{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:33:25Z","timestamp":1773801205970,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Council of Thailand (NRCT) and Mahidol University","award":["N42A650372"],"award-info":[{"award-number":["N42A650372"]}]},{"name":"Siriraj Foundation for Stem Cell Research","award":["D003276"],"award-info":[{"award-number":["D003276"]}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04352-9","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:49:40Z","timestamp":1773744580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human CD3 complex is required for the generation of T-cell receptor-like chimeric antigen receptor targeting WT1 in natural killer cells"],"prefix":"10.1007","volume":"75","author":[{"given":"Sudjit","family":"Luanpitpong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jirarat","family":"Poohadsuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parinya","family":"Samart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ponthip","family":"Pratumkaew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montira","family":"Janan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surapol","family":"Issaragrisil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"3","key":"4352_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers15030663","volume":"15","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y (2023) CAR-T: What is next? Cancers (Basel) 15(3):663. https:\/\/doi.org\/10.3390\/cancers15030663","journal-title":"Cancers (Basel)"},{"key":"4352_CR2","doi-asserted-by":"publisher","first-page":"1407001","DOI":"10.3389\/fonc.2024.1407001","volume":"14","author":"K Asghar","year":"2024","unstructured":"Asghar K, Zafar M, Holland E, Abduljabbar AB, Albagoush SA, Asghar N et al (2024) A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma. Front Oncol 14:1407001. https:\/\/doi.org\/10.3389\/fonc.2024.1407001","journal-title":"Front Oncol"},{"key":"4352_CR3","doi-asserted-by":"publisher","first-page":"1414264","DOI":"10.3389\/fimmu.2024.1414264","volume":"15","author":"R Yang","year":"2024","unstructured":"Yang R, Yang Y, Liu R, Wang Y, Yang R, He A (2024) Advances in CAR-NK cell therapy for hematological malignancies. Front Immunol 15:1414264. https:\/\/doi.org\/10.3389\/fimmu.2024.1414264","journal-title":"Front Immunol"},{"key":"4352_CR4","doi-asserted-by":"publisher","first-page":"1384039","DOI":"10.3389\/fimmu.2024.1384039","volume":"15","author":"JC Kong","year":"2024","unstructured":"Kong JC, Sa\u2019ad MA, Vijayan HM, Ravichandran M, Balakrishnan V, Tham SK et al (2024) Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges. Front Immunol 15:1384039. https:\/\/doi.org\/10.3389\/fimmu.2024.1384039","journal-title":"Front Immunol"},{"issue":"6","key":"4352_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41417-021-00307-7","volume":"28","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim M, Mohammadkhani N, Mahmoudi R, Gholizadeh M, Fakhr E, Cid-Arregui A (2021) TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential. Cancer Gene Ther 28(6):581\u2013589. https:\/\/doi.org\/10.1038\/s41417-021-00307-7","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"4352_CR6","doi-asserted-by":"publisher","first-page":"e004035","DOI":"10.1136\/jitc-2021-004035","volume":"10","author":"X Liu","year":"2022","unstructured":"Liu X, Xu Y, Xiong W, Yin B, Huang Y, Chu J et al (2022) Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1\/HLA-A2 for cancer immunotherapy. J Immunother Cancer 10(3):e004035. https:\/\/doi.org\/10.1136\/jitc-2021-004035","journal-title":"J Immunother Cancer"},{"issue":"17","key":"4352_CR7","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323\u20135337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0737","journal-title":"Clin Cancer Res"},{"key":"4352_CR8","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1038\/srep08924","volume":"5","author":"XW Qi","year":"2015","unstructured":"Qi XW, Zhang F, Wu H, Liu JL, Zong BG, Xu C et al (2015) Wilms\u2019 tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep 5:8924. https:\/\/doi.org\/10.1038\/srep08924","journal-title":"Sci Rep"},{"issue":"1","key":"4352_CR9","doi-asserted-by":"publisher","first-page":"2254557","DOI":"10.1080\/16078454.2023.2254557","volume":"28","author":"J Wu","year":"2023","unstructured":"Wu J, Yan H, Xiang C (2023) Wilms\u2019 tumor gene 1 in hematological malignancies: friend or foe? Hematology 28(1):2254557. https:\/\/doi.org\/10.1080\/16078454.2023.2254557","journal-title":"Hematology"},{"key":"4352_CR10","doi-asserted-by":"publisher","first-page":"102237","DOI":"10.1016\/j.tranon.2024.102237","volume":"52","author":"Q Nian","year":"2025","unstructured":"Nian Q, Lin Y, Zeng J, Zhang Y, Liu R (2025) Multifaceted functions of the wilms tumor 1 protein: from its expression in various malignancies to targeted therapy. Transl Oncol 52:102237. https:\/\/doi.org\/10.1016\/j.tranon.2024.102237","journal-title":"Transl Oncol"},{"issue":"15","key":"4352_CR11","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/j.molimm.2010.06.005","volume":"47","author":"OY Borbulevych","year":"2010","unstructured":"Borbulevych OY, Do P, Baker BM (2010) Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics. Mol Immunol 47(15):2519\u20132524. https:\/\/doi.org\/10.1016\/j.molimm.2010.06.005","journal-title":"Mol Immunol"},{"key":"4352_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1100\/tsw.2007.119","volume":"7","author":"Y Oka","year":"2007","unstructured":"Oka Y, Tsuboi A, Elisseeva OA, Nakajima H, Fujiki F, Kawakami M et al (2007) WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. ScientificWorldJournal 7:649\u2013665. https:\/\/doi.org\/10.1100\/tsw.2007.119","journal-title":"ScientificWorldJournal"},{"issue":"26","key":"4352_CR13","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","volume":"113","author":"U Keilholz","year":"2009","unstructured":"Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW et al (2009) A clinical and immunologic phase 2 trial of wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113(26):6541\u20136548. https:\/\/doi.org\/10.1182\/blood-2009-02-202598","journal-title":"Blood"},{"issue":"11","key":"4352_CR14","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1038\/leu.2015.125","volume":"29","author":"Q Zhao","year":"2015","unstructured":"Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF et al (2015) Affinity maturation of T-cell receptor-like antibodies for wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia 29(11):2238\u20132247. https:\/\/doi.org\/10.1038\/leu.2015.125","journal-title":"Leukemia"},{"issue":"1","key":"4352_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40164-022-00341-7","volume":"11","author":"X Wang","year":"2022","unstructured":"Wang X, Yang X, Yuan X, Wang W, Wang Y (2022) Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential. Exp Hematol Oncol 11(1):85. https:\/\/doi.org\/10.1186\/s40164-022-00341-7","journal-title":"Exp Hematol Oncol"},{"key":"4352_CR16","doi-asserted-by":"publisher","first-page":"5562630","DOI":"10.1155\/2021\/5562630","volume":"2021","author":"S Luanpitpong","year":"2021","unstructured":"Luanpitpong S, Poohadsuan J, Klaihmon P, Issaragrisil S (2021) Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic malignancies. J Immunol Res 2021:5562630. https:\/\/doi.org\/10.1155\/2021\/5562630","journal-title":"J Immunol Res"},{"issue":"1","key":"4352_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40164-024-00534-2","volume":"13","author":"P Klaihmon","year":"2024","unstructured":"Klaihmon P, Samart P, Rojanasakul Y, Issaragrisil S, Luanpitpong S (2024) Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion. Exp Hematol Oncol 13(1):67. https:\/\/doi.org\/10.1186\/s40164-024-00534-2","journal-title":"Exp Hematol Oncol"},{"key":"4352_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ebiom.2019.01.031","volume":"40","author":"N Mensali","year":"2019","unstructured":"Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR et al (2019) NK cells specifically TCR-dressed to kill cancer cells. EBioMedicine 40:106\u2013117. https:\/\/doi.org\/10.1016\/j.ebiom.2019.01.031","journal-title":"EBioMedicine"},{"issue":"9","key":"4352_CR19","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.3390\/cimb44090265","volume":"44","author":"KH Rasul","year":"2022","unstructured":"Rasul KH, Hussain A, Reilly H, Karvouni M, Dahlberg CIM, Al-Attar MS et al (2022) Assessment of T cell receptor complex expression kinetics in natural killer cells. Curr Issues Mol Biol 44(9):3859\u20133871. https:\/\/doi.org\/10.3390\/cimb44090265","journal-title":"Curr Issues Mol Biol"},{"key":"4352_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fimmu.2020.00257","volume":"11","author":"Y Akatsuka","year":"2020","unstructured":"Akatsuka Y (2020) TCR-like CAR-T cells targeting MHC-bound minor histocompatibility antigens. Front Immunol 11:257. https:\/\/doi.org\/10.3389\/fimmu.2020.00257","journal-title":"Front Immunol"},{"issue":"24","key":"4352_CR21","doi-asserted-by":"publisher","first-page":"13504","DOI":"10.3390\/ijms252413504","volume":"25","author":"AM Waaga-Gasser","year":"2024","unstructured":"Waaga-Gasser AM, B\u00f6ldicke T (2024) Genetically engineered T cells and recombinant antibodies to target intracellular neoantigens: current status and future directions. Int J Mol Sci 25(24):13504. https:\/\/doi.org\/10.3390\/ijms252413504","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4352_CR22","doi-asserted-by":"publisher","first-page":"200889","DOI":"10.1016\/j.omton.2024.200889","volume":"32","author":"S Luanpitpong","year":"2024","unstructured":"Luanpitpong S, Klaihmon P, Janan M, Kungwankiattichai S, Owattanapanich W, Kunacheewa C et al (2024) Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: experiences of an academic in Thailand. Mol Ther Oncol 32(4):200889. https:\/\/doi.org\/10.1016\/j.omton.2024.200889","journal-title":"Mol Ther Oncol"},{"issue":"2","key":"4352_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","volume":"29","author":"A Bairoch","year":"2018","unstructured":"Bairoch A (2018) The cellosaurus, a cell-line knowledge resource. J Biomol Tech 29(2):25\u201338. https:\/\/doi.org\/10.7171\/jbt.18-2902-002","journal-title":"J Biomol Tech"},{"key":"4352_CR24","doi-asserted-by":"publisher","DOI":"10.1261\/rna.2192803","author":"SA Stewart","year":"2003","unstructured":"Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS et al (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. https:\/\/doi.org\/10.1261\/rna.2192803","journal-title":"RNA"},{"issue":"11","key":"4352_CR25","doi-asserted-by":"publisher","first-page":"e27930","DOI":"10.1371\/journal.pone.0027930","volume":"6","author":"S W\u00e4lchli","year":"2011","unstructured":"W\u00e4lchli S, L\u00f8set G\u00c5, Kumari S, Johansen JN, Yang W, Sandlie I et al (2011) A practical approach to T-cell receptor cloning and expression. PLoS ONE 6(11):e27930. https:\/\/doi.org\/10.1371\/journal.pone.0027930","journal-title":"PLoS ONE"},{"key":"4352_CR26","doi-asserted-by":"publisher","first-page":"864868","DOI":"10.3389\/fimmu.2022.864868","volume":"13","author":"S McComb","year":"2022","unstructured":"McComb S, Nguyen T, Shepherd A, Henry KA, Bloemberg D, Marcil A et al (2022) Programmable attenuation of antigenic sensitivity for a nanobody-based EGFR chimeric antigen receptor through hinge domain truncation. Front Immunol 13:864868. https:\/\/doi.org\/10.3389\/fimmu.2022.864868","journal-title":"Front Immunol"},{"issue":"12","key":"4352_CR27","doi-asserted-by":"publisher","first-page":"e5021","DOI":"10.21769\/BioProtoc.5021","volume":"14","author":"A Shepherd","year":"2024","unstructured":"Shepherd A, Bennychen B, Ahmed Z, Weeratna RD, McComb S (2024) A flow cytometry-based method for assessing CAR cell binding kinetics using stable CAR jurkat cells. Bio Protoc 14(12):e5021. https:\/\/doi.org\/10.21769\/BioProtoc.5021","journal-title":"Bio Protoc"},{"issue":"W1","key":"4352_CR28","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC et al (2022) DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res 50(W1):W216\u2013W221. https:\/\/doi.org\/10.1093\/nar\/gkac194","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"4352_CR29","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G et al (2023) SRplot: a free online platform for data visualization and graphing. PLoS ONE 18(11):e0294236. https:\/\/doi.org\/10.1371\/journal.pone.0294236","journal-title":"PLoS ONE"},{"key":"4352_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf1237","author":"P Lo Surdo","year":"2025","unstructured":"Lo Surdo P, Iannuccelli M, Karis K, Meo E, Omidi P, Tosoni M et al (2025) SIGNOR 4.0: the 2025 update with focus on phosphorylation data. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkaf1237","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"4352_CR31","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","volume":"72","author":"SS Mun","year":"2023","unstructured":"Mun SS, Meyerberg J, Peraro L, Korontsvit T, Gardner T, Malviya M et al (2023) Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunol Immunother 72(11):3773\u20133786. https:\/\/doi.org\/10.1007\/s00262-023-03529-w","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"4352_CR32","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/ijms20163912","volume":"20","author":"Y Shen","year":"2019","unstructured":"Shen Y, Li YM, Zhou JJ, Zhou Z, Xu YC, Zhao WB et al (2019) The antitumor activity of TCR-mimic antibody-drug conjugates (TCRm-ADCs) targeting the intracellular wilms tumor 1 (WT1) oncoprotein. Int J Mol Sci 20(16):3912. https:\/\/doi.org\/10.3390\/ijms20163912","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4352_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/jjco\/hyp194","volume":"40","author":"H Sugiyama","year":"2010","unstructured":"Sugiyama H (2010) WT1 (Wilms\u2019 tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 40(5):377\u2013387. https:\/\/doi.org\/10.1093\/jjco\/hyp194","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"4352_CR34","doi-asserted-by":"publisher","first-page":"e003715","DOI":"10.1136\/jitc-2021-003715","volume":"10","author":"LT Morton","year":"2022","unstructured":"Morton LT, Wachsmann TLA, Meeuwsen MH, Wouters AK, Remst DFG, van Loenen MM et al (2022) T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion. J Immunother Cancer 10(3):e003715. https:\/\/doi.org\/10.1136\/jitc-2021-003715","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4352_CR35","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3324\/haematol.2017.187385","volume":"103","author":"BA Williams","year":"2018","unstructured":"Williams BA, Wang XH, Leyton JV, Maghera S, Deif B, Reilly RM et al (2018) CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. Haematologica 103(10):1720\u20131729. https:\/\/doi.org\/10.3324\/haematol.2017.187385","journal-title":"Haematologica"},{"key":"4352_CR36","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3389\/fimmu.2018.02873","volume":"9","author":"KM Snyder","year":"2018","unstructured":"Snyder KM, Hullsiek R, Mishra HK, Mendez DC, Li Y, Rogich A et al (2018) Expression of a recombinant high affinity IgG Fc receptor by engineered NK cells as a docking platform for therapeutic mAbs to target cancer cells. Front Immunol 9:2873. https:\/\/doi.org\/10.3389\/fimmu.2018.02873","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"4352_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294(1\u20132):15\u201322. https:\/\/doi.org\/10.1016\/j.jim.2004.08.008","journal-title":"J Immunol Methods"},{"issue":"3","key":"4352_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/cancers12030706","volume":"12","author":"A Pfefferle","year":"2020","unstructured":"Pfefferle A, Huntington ND (2020) You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy. Cancers (Basel) 12(3):706. https:\/\/doi.org\/10.3390\/cancers12030706","journal-title":"Cancers (Basel)"},{"key":"4352_CR39","doi-asserted-by":"publisher","first-page":"992232","DOI":"10.3389\/fimmu.2022.992232","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Song W, Li Z, Zhang M (2022) Preclinical and clinical studies of CAR-NK-cell therapies for malignancies. Front Immunol 13:992232. https:\/\/doi.org\/10.3389\/fimmu.2022.992232","journal-title":"Front Immunol"},{"issue":"4","key":"4352_CR40","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388\u2013398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548","journal-title":"Cancer Discov"},{"key":"4352_CR41","doi-asserted-by":"publisher","first-page":"215699","DOI":"10.1016\/j.canlet.2022.215699","volume":"538","author":"G Xu","year":"2022","unstructured":"Xu G, Luo Y, Wang H, Wang Y, Liu B, Wei J (2022) Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Lett 538:215699. https:\/\/doi.org\/10.1016\/j.canlet.2022.215699","journal-title":"Cancer Lett"},{"issue":"3","key":"4352_CR42","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00262-022-03275-5","volume":"72","author":"S Li","year":"2023","unstructured":"Li S, Zhang C, Shen L, Teng X, Xiao Y, Yu B et al (2023) TCR extracellular domain genetically linked to CD28, 2B4\/41BB and DAP10\/CD3\u03b6 -engineered NK cells mediates antitumor effects. Cancer Immunol Immunother 72(3):769\u2013774. https:\/\/doi.org\/10.1007\/s00262-022-03275-5","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04352-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04352-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04352-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:02:12Z","timestamp":1773788532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04352-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4352"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04352-9","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Siriraj Institutional Review Board (COA nos. Si 966\/2020 and 564\/2018) and conducted in accordance with the principles of the 1975 Declaration of Helsinki. The cell lines used in this study were purchased from ATCC, JCRB Cell Bank, and Thermo Fisher Scientific.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"107"}}